Last reviewed · How we verify
NCT04422925
s100β, NSE n GFAP in Living Donor Hepatectomy and Delirium
trial testing Living Donor Hepatectomy in Donor Site Complication in 56 participants. Completed in 1 December 2021.
1 November 2021
Quick facts
| Lead sponsor | Akdeniz University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 1 September 2019 |
| Primary completion | 1 November 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Living Donor Hepatectomy
Conditions studied
- Donor Site Complication — all drugs for Donor Site Complication →
- Delirium — all drugs for Delirium →
- Uremic Encephalopathy — all drugs for Uremic Encephalopathy →
- Neurologic Manifestations — all drugs for Neurologic Manifestations →
Sponsor
Akdeniz University
Who can join
Adults 18 to 77, any sex, with Donor Site Complication or Delirium. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The post-operative delirium picture is a serious and common complication seen after any major surgery, including hepatic resection. Patients who will be planned to undergo donor hepatectomy for liver transplantation will be included in the study. Basic clinical and demographic information of patients undergoes donor hepatectomy will be recorded before surgery. The anatomical parameters such as liver volume, medications performed during the surgery, complications, bleeding amounts, fluids given, blood and blood products, vital signs during surgery, fluid balance, duration of surgery, recovery length at post-operative period, complications after surgery, approaches to complications, analgesics and other medications used, hemogram and other biochemical parameters (electrolytes, albumin, liver frontier tests, etc.), weight status, vital signs, duration of intensive care, post-operative VAS scores, drainage and information such as length of stay, length of hospital stay, the healing time of the wound will also be recorded. During the hospitalization, the delirium status of the patients will be evaluated with a delirium evaluation scale by consultant doctor. Blood will be taken for the measurement of S100β, NSE, and GFAP levels one day before donor hepatectomy and following day of hepatectomy, 3rd day, and 7th day in the post-operative period. The plasma of the blood taken will be separated and stored at -80 0C until working. Laboratory values are taken from the patients before the operation will be recorded over the system. The relationship between the results obtained and the delirium evaluation scores performed on the days followed will be evaluated. This study aims to analyze the delirium incidence and post-operative early S100β, NSE, and GFAP levels within the first week following the hepatectomy performed in live donors for liver transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04422925
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Living Donor Hepatectomy
Trials testing the same drug.
- NCT07301853 — Longitudinal Follow-up and Health-Related Outcomes in Liver Transplant Recipients and Living Donors · recruiting
Other recruiting trials for Donor Site Complication
Currently open trials in the same condition.
- NCT07453927 — Blue Light for Donor Site Healing in Burn Patients · NA · recruiting
- NCT07057557 — Aloe Vera vs Paraffin Tulle Dressings for Pain Management in Split Thickness Skin Graft Donor Sites · NA · recruiting
Other Akdeniz University trials
Trials by the same sponsor.
- NCT07581132 — Investigation of the Effect of Structured Energy Conservation Techniques Training on COPD Patients · NA · not yet recruiting
- NCT07469345 — Bruxism, Pelvic Pain, Erectile Dysfunction, and Anxiety in Young Adult Men · enrolling by invitation
- NCT07507279 — Technology-based Hand Rehabilitation in Older People · NA · not yet recruiting
- NCT07437924 — Bruxism and Pelvic Floor Dysfunction in Young Women · enrolling by invitation
- NCT07497308 — GDF-15 and Early Outcomes After LVAD Implantation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04422925 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Akdeniz University
- Last refreshed: 11 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04422925.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing